EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

OUTCOME OF DIFFERENT DOSES OF LABETALOL FOR CONTROLLING HEMODYNAMIC RESPONSES TO LARYNGOSCOPY AND TRACHEAL INTUBATION IN HYPERTENSIVE PATIENTS

Dr. Sheikh Rukun Uddin Ahmed*

ABSTRACT

Background: Now-a-days, labetalol is used for controlling hemodynamic responses to laryngoscopy and tracheal intubation in hypertensive patients. Objective: In this study our main goal is to evaluate the outcome of different doses of labetalol for controlling hemodynamic responses to laryngoscopy and tracheal intubation in hypertensive patients. Method: This a prospective, randomized, placebo controlled, double-blinded trial is conducted in tertiary medical college and hospital from January 2019 to December 2020. Where a total of 150 patients, ASA physical status I and II, aged 18–60 years, undergoing elective surgical procedures, requiring general anesthesia and orotracheal intubation were included in the study. Where in Group L1 – Syringe contained Labetalol (0.15 mg/kg diluted with 0.9% saline to 5 ml), Group L2 – Syringe contained Labetalol (0.3 mg/kg diluted with 0.9% saline to 5 ml) and Group C – Syringe contained 5 ml of 0.9% saline. Results: During the study, majority were belong to 41-50 years age group, 40% and 61.20% were female. Besides that, there was statistically significant difference in heart rate throughout study time between the L1 and control group (P < 0.001), and L2 and control group (P < 0.001). in addition, There was no significant difference in DBP between L1 and L2 at intubation and 1 min post-intubation. However, there was statistically significant difference in DBP between L1 and L2 group at 3 min, 5 min and 10 min post intubation (P < 0.001). Rate pressure product was significantly less at the time of intubation in the L1 and L2 group (P < 0.001) as compared to the control group. Conclusion: labetalol at both 0.15 mg/kg and 0.3 mg/kg iv dosages is efficacious in lowering hemodynamic responses to direct laryngoscopy and tracheal intubation in hypertensive patients in a dose-dependent manner. Bradycardia is more prevalent in patients taking labetalol at a dosage of 0.3 mg/kg.

Keywords: Laryngoscopy, tracheal intubation, labetalol.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • EJPMR: AUGUST ISSUE PUBLISHED

    AUGUST Issue has been successfully launched on 1 August 2022.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 August 2022 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database